Xu Y, Hagege J, Mougenot B, Sraer J D, Rønne E, Rondeau E
Service de Néphrologie A, Hôpital Tenon, Paris, France.
Kidney Int. 1996 Dec;50(6):2011-9. doi: 10.1038/ki.1996.523.
Renal thrombotic microangiopathy is characterized by glomerular and vascular thrombosis. The persistancy of fibrin deposits may result from imbalance between plasminogen activation and inhibition. In the present study, we used immunohistochemistry and in situ hybridization techniques to determine the localization of urokinase-type (u-PA) and tissue-type (t-PA) plasminogen activators, type 1 plasminogen activator inhibitor (PAI-1) and membrane receptor for u-PA (uPA-R) antigen and their sites of synthesis in renal thrombotic microangiopathy (N = 10) as compared to acute tubular necrosis (N = 5) and normal human kidneys (N = 7). We found an induction of PAI-1 and uPA-R expression in glomeruli and in arterial walls in renal thrombotic microangiopathy. In addition, the induction of uPA-R expression was also found in some tubular epithelial cells. In most case, local synthesis of PAI-1 and uPA-R was confirmed by in situ hybridization with the corresponding cDNA probes. In contrast, using similar techniques PAI-1 and uPA-R antigens and messenger RNAs could not be detected in normal kidneys. In both renal thrombotic microangiopathy and normal kidneys, t-PA mRNA was detected in large amounts in all glomeruli and in vascular endothelial cells, but t-PA antigen was only detected in a limited number of glomerular and arterial endothelial cells, whereas it was strongly expressed by all venous endothelial cells. Although u-PA antigen was found in almost all tubular sections, u-PA mRNA was only found in tubular epithelial cells in the deep cortex and the outer medulla. Our results indicate that there is an up-regulation of PAI-1 and u-PA-R expression in the glomeruli and in the arterial walls of thrombotic microangiopathy. The local release of PAI-1 could play a role in the persistancy of fibrin deposition and the further development of fibrotic lesions. Whether uPA-R plays a pathogenic role in the development of glomerular and vascular lesions, or is involved in the repair process of these lesion, remains to be elucidated.
肾血栓性微血管病的特征是肾小球和血管血栓形成。纤维蛋白沉积的持续存在可能是由于纤溶酶原激活与抑制之间的失衡所致。在本研究中,我们使用免疫组织化学和原位杂交技术,确定了尿激酶型(u-PA)和组织型(t-PA)纤溶酶原激活剂、1型纤溶酶原激活剂抑制剂(PAI-1)和u-PA膜受体(uPA-R)抗原的定位及其在肾血栓性微血管病(n = 10)中的合成部位,并与急性肾小管坏死(n = 5)和正常人类肾脏(n = 7)进行了比较。我们发现,在肾血栓性微血管病中,肾小球和动脉壁中PAI-1和uPA-R表达上调。此外,在一些肾小管上皮细胞中也发现了uPA-R表达上调。在大多数情况下,通过与相应的cDNA探针进行原位杂交证实了PAI-1和uPA-R的局部合成。相比之下,使用类似技术在正常肾脏中未检测到PAI-1和uPA-R抗原及信使RNA。在肾血栓性微血管病和正常肾脏中,在所有肾小球和血管内皮细胞中均大量检测到t-PA mRNA,但t-PA抗原仅在有限数量的肾小球和动脉内皮细胞中检测到,而在所有静脉内皮细胞中均强烈表达。尽管在几乎所有肾小管切片中都发现了u-PA抗原,但u-PA mRNA仅在深皮质和外髓质的肾小管上皮细胞中发现。我们的结果表明,在血栓性微血管病的肾小球和动脉壁中,PAI-1和u-PA-R表达上调。PAI-1的局部释放可能在纤维蛋白沉积的持续存在和纤维化病变的进一步发展中起作用。uPA-R在肾小球和血管病变的发展中是否起致病作用,或是否参与这些病变的修复过程,仍有待阐明。